Trials / Unknown
UnknownNCT04060550
Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum
Investigate the Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Responses in the Eczema Herpeticum Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (estimated)
- Sponsor
- National Jewish Health · Academic / Other
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study investigates whether blood monocytes' surface bound- immunoglobulin E affects the innate immune responses against herpes simplex viruses in atopic dermatitis patients with eczema herpeticum.
Detailed description
Some of atopic dermatitis patients (AD) have severe herpes simplex viral (HSV) infections, which could cause erosive skin lesions all over the body. This condition is termed as eczema herpeticum (ADEH+). Scientists have found that ADEH+ patients have significantly increased blood immunoglobulin (Ig) E compared to AD patients without eczema herpeticum and healthy people. Increased IgE in blood could bound to immune cells' surface, such as monocytes. Since monocytes serve as the first line defense to fight viral infection, their surface-bound IgE may interfere their anti-viral immune responses, and consequently results in more severe viral infections. The purpose of this study is to learn more about how increased IgE affect body's immune ability to fight herpes simplex viruses. This study includes three groups: AD patient without eczema herpeticum complication(ADEH-); AD patient with eczema herpeticum complication(ADEH+) and healthy controls. Study results will be compared between groups.
Conditions
- Atopic Dermatitis With a History of Eczema Herpeticum
- Atopic Dermatitis Without a History of Eczema Herpeticum
- Health Controls Without Atopy
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Xolair | This is in vitro mechanistic study. No drug will be given in vivo to patients. |
Timeline
- Start date
- 2020-01-09
- Primary completion
- 2021-07-31
- Completion
- 2021-07-31
- First posted
- 2019-08-19
- Last updated
- 2021-03-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04060550. Inclusion in this directory is not an endorsement.